Mitochondrial comparative proteomics of human ovarian cancer cells and their platinum-resistant sublines.
Resistance to platinum-based chemotherapy is the major obstacle to successful treatment of ovarian cancer. It is evident that mitochondrial defects and the dysfunctions of oxidative phosphorylation and energy production in ovarian cancer cells were directly related to their resistance to platinum drugs. Using 2-D DIGE, we compared mitochondrial proteins from two platinum-sensitive human ovarian cancer cell lines (SKOV3 and A2780) with that of four platinum-resistant sublines (SKOV3/CDDP, SKOV3/CBP, A2780/CDDP, and A2780/CBP). Among the 236 differentially expressed spots, five mitochondrial proteins (ATP-α, PRDX3, PHB, ETF, and ALDH) that participate in the electron transport respiratory chain were identified through mass spectrometry. All of them are downregulated in one or two of the platinum-resistant cell lines. Three proteins (ATP-α, PRDX3, and PHB) were validated by using western blot and immunohistochemistry. There is a significant decrease of PHB in tumor tissues from ovarian cancer patients who were resistant to platinum-based chemotherapies. This is the first direct mitochondrial proteomic comparison between platinum-sensitive and resistant ovarian cancer cells. These studies demonstrated that 2-D DIGE-based proteomic analysis could be a powerful tool to investigate limited mitochondrial proteins, and the association of PHB expression with platinum resistance indicates that mitochondria defects may contribute to platinum resistance in ovarian cancer cells.
Dai
Zhiqin
Z
Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China.
Yin
Jie
J
He
Haojie
H
Li
Wenrui
W
Hou
Chunmei
C
Qian
Xiaohong
X
Mao
Ning
N
Pan
Lingya
L
D015153:Blotting, Western; D045744:Cell Line, Tumor; D019008:Drug Resistance, Neoplasm; D015180:Electrophoresis, Gel, Two-Dimensional; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008928:Mitochondria / Q000737:chemistry; D024101:Mitochondrial Proteins / Q000737:chemistry / Q000378:metabolism*; D009944:Organoplatinum Compounds / Q000494:pharmacology*; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D061105:Peroxiredoxin III; D054464:Peroxiredoxins / Q000737:chemistry / Q000378:metabolism; D000091402:Prohibitins; D040901:Proteomics / Q000379:methods*; D012097:Repressor Proteins / Q000737:chemistry / Q000378:metabolism; D015203:Reproducibility of Results; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
D024101:Mitochondrial Proteins; D009944:Organoplatinum Compounds; C000717328:PHB protein, human; D000091402:Prohibitins; D012097:Repressor Proteins; C516115:PRDX3 protein, human; D061105:Peroxiredoxin III; D054464:Peroxiredoxins